Compare Crispr Therapeutics AG (CRSP) vs Dropbox Inc (DBX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Dropbox Inc — how do they compare? Crispr Therapeutics AG trades at $51.11 (market cap $4.88B), while Dropbox Inc trades at $34.15 (market cap $7.42B). The key difference: Dropbox Inc is the larger of the two by market cap, and Dropbox Inc is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Dropbox Inc for 97 Days on average.
| CRSP | DBX | |
|---|---|---|
Market Cap | $4.88B | $7.42B |
Volume | 2,861,747 | 3,061,580 |
Sector | Health | Technology |
52-Week High | $74.92 | $37.74 |
52-Week Low | $44.34 | $22.06 |
Typical Hold Time | 77 Days | 97 Days |
Enterprise Value | $3.30B | $10.29B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $52.35, down 3.06% on the day, with a bearish technical signal and negative profitability metrics. The company reported no revenue in 2025 with a net loss of $581.60M, though recent earnings beat expectations in Q2 2026. Analyst sentiment remains positive with a $67.83 price target and 57.9% buy ratings, supported by upcoming clinical data catalysts for its gene-editing therapies.
The stock faces significant fundamental challenges with negative margins and cash burn, but strong analyst support and pipeline progress offer long-term potential. Key risks include clinical trial outcomes and commercialization execution, while institutional interest and positive media coverage provide near-term catalysts for investor consideration.
Dropbox (DBX) trades at $33.08, down 1.93% amid bearish technical signals and mixed analyst sentiment. The company maintains strong profitability with 79.72% gross margins and has beaten earnings estimates for three consecutive quarters. However, negative shareholder equity and recent insider selling create headwinds. Technical indicators show bearish momentum with support at $32 and resistance at $34.
Outlook remains cautious despite solid fundamentals. The stock faces valuation concerns with a P/E of 18.86 and mixed analyst ratings (37.5% buy, 31.25% hold/sell each). Key risks include stagnant revenue growth, high debt levels, and competitive pressures in cloud storage. The consensus price target of $26.83 suggests potential downside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Dropbox Inc
Dropbox is a leading provider of cloud-storage and content collaboration tools with an emphasis on individuals and SMB. The company was founded in 2007 and was a pioneer in cloud storage and cross-platform file syncing. Utilizing inorganic and organic means, the firm has been working on diversifying its product mix and pivoting away from the cloud-storage space.
Read more on DBX →
